“Biological evaluation of 2,3-dioxoindolin-N-phenylacetamide derivatives as potent CDC25B and PTP1B phosphatase inhibitors” (2020) Brazilian Journal of Pharmaceutical Sciences, 56, p. e00222. doi:10.1590/s2175-97902019000400222.